Target-related Affinity Profiling: Telik's lead discovery technology

Current Topics in Medicinal Chemistry

Volumn 5, Issue 4, 2005, Pages 371-381

  Beroza, Paul ^a   Damodaran, Komath ^a   Lum, Robert T ^a  

^a Telik Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; ACEMETACIN; CARBOXYLESTERASE; CARBOXYLESTERASE INHIBITOR; CARPROFEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; DICLOFENAC; DIFLUNISAL; ENZYME INHIBITOR; ETODOLAC; FENBUFEN; IBUPROFEN; INDOMETACIN; INDOPROFEN; ISOXICAM; KETOPROFEN; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR AGONIST; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PIRPROFEN; SULINDAC; TENOXICAM; UNCLASSIFIED DRUG;

BINDING AFFINITY; CHEMICAL STRUCTURE; COMBINATORIAL CHEMISTRY; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TECHNOLOGY;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR BIOLOGY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN BINDING; RECEPTORS, DRUG;

EID: 19944391612     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053828394     Document Type: Review

References (29)

1. Patterson, D. E.; Cramer, R. D.; Ferguson, A. M.; Clark, R. D.; Weinberger, L. E. Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. J. Med. Chem. 1996, 39, 3049-3059.
2. Ingram, V. M. Gene mutations in human haemoglobin: the chemical difference between normal and sickle haemoglobin. Nature, 1957, 180, 326-328.
3. Shafer, R. W.; Kantor, R.; Gonzales, M. J. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews, 2000, 2, 211-228.
4. Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W.; Mural, R.J.; Sutton, G.G.; Smith, H.O.; Yandell, M.; Evans, C.A.; Holt, R.A.; Gocayne, J.D.; Amanatides, P.; Ballew, R.M.; Huson, D.H.; Wortman, J.R.; Zhang, Q.; Kodira, C.D.; Zheng, X.H.; Chen, L.; Skupski, M.; Subramanian, G.; Thomas, P.D.; Zhang, J.; Gabor Miklos, G.L.; Nelson, C.; Broder, S.; Clark, A.G.; Nadeau, J.; McKusick, V.A.; Zinder, N.; Levine, A.J.; Roberts, R.J.; Simon, M.; Slayman, C.; Hunkapiller, M.; Bolanos, R.; Delcher, A.; Dew, I.; Fasulo, D.; Flanigan, M.; Florea, L.; Halpern, A.; Hannenhalli, S.; Kravitz, S.; Levy, S.; Mobarry, C.; Reinert, K.; Remington, K.; Abu-Threideh, J.; Beasley, E.; Biddick, K.; Bonazzi, V.; Brandon, R.; Cargill, M.; Chandramouliswaran, I.; Charlab, R.; Chaturvedi, K.; Deng, Z.; Di, Francesco, V.; Dunn, P.; Eilbeck, K.; Evangelista, C.; Gabrielian, A.E.; Gan, W.; Ge, W.; Gong, F.; Gu, Z.; Guan, P.; Heiman, T.J.; Higgins, M.E.; Ji, R.R.; Ke, Z.; Ketchum, K.A.; Lai, Z.; Lei, Y.; Li, Z.; Li, J.; Liang, Y.; Lin, X.; Lu, F.; Merkulov, G.V.; Milshina, N.; Moore, H.M.; Naik, A.K.; Narayan, V.A.; Neelam, B.; Nusskern, D.; Rusch, D.B.; Salzberg, S.; Shao, W.; Shue, B.; Sun, J.; Wang, Z.; Wang, A.; Wang, X.; Wang, J.; Wei, M.; Wides, R.; Xiao, C.; et al. The sequence of the human genome. Science, 2001, 291, 1304-1351.
5. Bohacek, R. S.; McMartin, C.; Guida, W. C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev., 1996, 16, 3-50.
6. Entzeroth, M. Emerging trends in high-throughput screening. Curr. Opin. Pharmacol., 2003, 3, 522-529.
7. Engels, M. F.; Venkatarangan, P. Smart screening: approaches to efficient HTS. Curr. Opin. Drug Discov. Devel., 2001, 4, 275-283.
8. Young, S. S.; Lam, R. L.; Welch, W. J. Initial compound selection for sequential screening. Curr. Opin. Drug Discov. Devel., 2002, 5, 422-427.
9. Bajorath, J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov., 2002, 1, 882-894.
10. Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev., 2003, 23, 302-321.
11. Walters, W. P.; Namchuk, M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov., 2003, 2, 259-266.
12. Xue, L.; Bajorath, J. Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen, 2000, 3, 363-372.
13. Kubinyi, H. The Quantitative Analysis of Structure-Activity Relationships. Burger's Medicinal Chemistry and Drug Discovery, Fifth ed.; John Wiley and Sons: New York, 1995, pp 497-571.
14. Xue, L.; Godden, J. W.; Bajorath, J. Database searching for compounds with similar biological activity using short binary bit string representations of molecules. J. Chem. Inf. Comput. Sci., 1999, 39, 881-886.
15. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf Comput. Sci., 2002, 42, 1273-1280.
16. Jaccard, P. The distribution of the flora of the alpine zone. New Phytologist, 1912, 11, 37-50.
17. Martin, Y. C.; Kofton, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity? J. Med. Chem., 2002, 45, 4350-4358.
18. McGregor, M. J.; Muskal, S. M. Pharmacophore fingerprinting. 1. Application to QSAR and focused library design. J. Chem. Inf. Comput. Sci., 1999, 39, 569-574.
19. Mason, J. S.; Good, A. C.; Martin, E. J. 3-D pharmacophores in drug discovery. Curr. Pharm. Des., 2001, 7, 567-597.
20. Putta, S.; Lemmen, C.; Beroza, P.; Greene, J. A novel shape-feature based approach to virtual library screening. J. Chem. Inf. Comput. Sci., 2002, 42, 1230-1240.
21. Kauvar, L.M.; Higgins, D.L.; Villar, H.O.; Sportsman, J.R.; Engqvist-Goldstein, A.; Bukar, R.; Bauer, K.E.. Dilley, H.; Rocke, D.M. Predicting ligand binding to proieins by affinity fingerprinting. Chem. Biol., 1995, 2, 107-118.
22. Kauvar, L. M.; Villar, H. O.; Sportsman, J. R.; Higgins, D. L.; Schmidt, D. E., Jr. Protein affinity map of chemical space. J. Chromatogr. B Biomed. Sci. Appl., 1998, 715, 93-102.
23. Reisine, T.; Pasternak, G. Opioid analgesics and antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth ed.; McGraw-Hill: New York, 1996, pp 521-555.
24. Dixon, S. L.; Villar, H. O. Bioactive diversity and screening library selection via affinity fingerprinting. J. Chem. Inf. Comput. Sci., 1998, 38, 1192-1203.
25. Hsu, N.; Cai, D.; Damodaran, K.; Gomez, R.F.; Keck, J.G.; Laborde, E.; Lum, R.T.; Macke, T.J.; Martin, G.; Schow, S.R.; Simon, R.J.; Villar, H.O.; Wick, M.M.; Beroza, P.Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints. J. Med. Chem., 2004, 47, 4875-4880.
26. Wadkins, R.M.; Hyatt, J.L.; Yoon, K.J.; Morton, C.L.; Lee, R.E.; Damodaran, K.; Beroza, P.; Danks, M.K.; Potter, P.M. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol. Pharmacol., 2004, 65, 1336-1343.
27. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
28. Ball, S. E.; Scatina, J. A.; Sisenwine, S. F.; Fisher, G. L. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem. Toxicol., 1995, 18, 1-28.
29. Pagliara, A.; Reist, M.; Geinoz, S.; Carrupt, P. A.; Testa, B. Evaluation and prediction of drug permeation. J. Pharm. Pharmacol., 1999, 51, 1339-1357.